Our recommendations help practitioners and commissioners get the best care to people, fast, while ensuring value for the taxpayer.
Around 20,000 children and young people with type 1 diabetes in England now benefit from life-changing 'artificial pancreas' technology, recommended by NICE.
The benefits from donanemab (also called Kisunla and made by Eli Lilly) and lecanemab (also called Leqembi and made by Eisai) - remain too small to justify the additional cost to the NHS, one of our independent committees has concluded following consultation.
People in England will become the first in the world to receive belantamab mafodotin for this indication following our recommendation and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year.
Around 3,000 deaths and 5,500 hospital admissions in England caused by chronic heart failure could be prevented each year following our updated draft guideline on medical treatment of the disease.
Best practice resources for practitioners and commissioners.
Useful sources of information and advice for healthcare professionals, patients, parents and carers.
Summaries of evidence and advice on common health topics (CKS)
Our NICE Advice service will guide you there.
Get reliable scientific advice and NHS insights, direct from NICE. We support companies seeking nationwide adoption of the best treatments and care.
